רווח תפעולי לפני ניכוי פחת: Pharming Group (PHAR)

Pharming Group N.V. relies on transparent European governance and global distribution networks. Diversification through the treatment of orphan diseases balances research and development costs. This chart on GURU.Markets shows that EBITDA currently stands at 46.11, serving as a navigator for cash flow. Meanwhile, reliance on third-party CMO plants is mitigated by long-term contracts.

Absolute operating profit measures the cash flow from core operations before depreciation and interest. This metric determines the business's actual ability to generate cash flows, excluding the impact of accounting policies. By analyzing absolute EBITDA trends, an investor assesses the resilience of profits to external shocks. For Pharming Group N.V. (PHAR), the stability of this line confirms market dominance in the orphan drug segment. The absence of competitors allows the company to maintain high margins and minimize revenue volatility.